SpyGlass Pharma Reports 37 Percent Intraocular Pressure Reduction in Four-Year Glaucoma Implant Study
SpyGlass Pharma announced four-year interim results from its first-in-human clinical trial evaluating the Bimatoprost Drug Pad-IOL System, an intraocular lens implant designed to treat mild-to-moderate open-angle glaucoma or ocular hypertension during cataract surgery, according to Investing.com.
Key Clinical Takeaways:
- Mean intraocular pressure across all dosage groups dropped 37%, moving from a baseline of 25.1 to 15.9 mmHg.
- Eighty-six percent of participating patients maintained their target pressure without using any supplemental eye drops.
- Ninety percent of patients sustained a corrected distance visual acuity of 20/25 or better through the four-year mark.
Four-Year Pressure Reductions in the Initial Cohort
The trial enrolled 23 patients across three dosage tiers of 75 micrograms, 150 micrograms, and 300 micrograms. By the four-year evaluation point, one patient had moved abroad and another discontinued participation after receiving an oncology diagnosis, leaving 21 evaluable subjects. Across these remaining patients, researchers documented a drop in mean intraocular pressure from 25.1 ± 2.5 mmHg down to 15.9 ± 2.8 mmHg. Data collected by the company showed that 18 of the 21 evaluable patients required zero supplemental intraocular pressure-lowering eye drops at the four-year check.
Drug-Delivery Pad Shows Efficacy for Four Years
The evaluated technology combines a standard cataract replacement lens with an attached drug-delivery pad. Patrick Mooney, chief executive officer at SpyGlass Pharma, stated in the company disclosure that this marks the first time a sustained-release drug implant for glaucoma has demonstrated safety and efficacy persisting for four years. The specific device utilized in the initial human trial was engineered to release bimatoprost for up to seven years. In contrast, the version currently moving through Phase III clinical evaluation is designed to continuously dispense the medication for a three-year duration. Bimatoprost itself is a prostaglandin analog that received initial regulatory approval from the U.S. Food and Drug Administration in 2001 as a topical drop to lower elevated eye pressure.
Future Regulatory Path and Trial Timeline
The single-center, prospective first-in-human study is structured to track patient evaluations out to 2029. Investigators reported zero product-related adverse events among the cohort through the four-year analysis window. Following the completion of current milestones, SpyGlass Pharma intends to coordinate with the U.S. Food and Drug Administration to pursue a new drug application via the 505(b)(2) regulatory pathway.